Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy

PURPOSE: The regimen including concurrent docetaxel, doxorubicin, and cyclophosphamide (TAC) has been categorized as an important risk factor for febrile neutropenia (FN). This comparative study examined the clinical impact of long-acting granulocyte colony-stimulating factor (G-CSF) (pegfilgrastim)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Breast Cancer
Autors principals: Jeon, Ye Won, Lim, Seung Taek, Gwak, HongKi, Park, Seon Young, Suh, Young Jin
Format: Artigo
Idioma:Inglês
Publicat: Korean Breast Cancer Society 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7604368/
https://ncbi.nlm.nih.gov/pubmed/33154827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4048/jbc.2020.23.e52
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars